Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.
The latest drug development news and highlights from our US FDA Performance Tracker.
Pfizer’s Vizimpro has been endorsed by an expert panel in India, paving the way for its potential introduction on the market, where other EGFR inhibitors including AstraZeneca’s Tagrisso have a head start.